LT3484502T - Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė - Google Patents

Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė

Info

Publication number
LT3484502T
LT3484502T LTEPPCT/US2017/029953T LTUS2017029953T LT3484502T LT 3484502 T LT3484502 T LT 3484502T LT US2017029953 T LTUS2017029953 T LT US2017029953T LT 3484502 T LT3484502 T LT 3484502T
Authority
LT
Lithuania
Prior art keywords
aging
treatment
blood plasma
cognitive disorders
plasma fractions
Prior art date
Application number
LTEPPCT/US2017/029953T
Other languages
English (en)
Inventor
David Bell
Ian GALLAGER
Steven P. Braithwaite
S. Sakura Minami
Vu DANG
Joe Mccracken
Karoly Nikolich
Original Assignee
Alkahest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest, Inc. filed Critical Alkahest, Inc.
Publication of LT3484502T publication Critical patent/LT3484502T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2017/029953T 2016-08-18 2017-04-27 Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė LT3484502T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376529P 2016-08-18 2016-08-18
US201662412258P 2016-10-24 2016-10-24
PCT/US2017/029953 WO2018034712A1 (en) 2016-08-18 2017-04-27 Blood plasma fractions as a treatment for aging-associated cognitive disorders

Publications (1)

Publication Number Publication Date
LT3484502T true LT3484502T (lt) 2021-12-10

Family

ID=61196950

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/029953T LT3484502T (lt) 2016-08-18 2017-04-27 Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė

Country Status (28)

Country Link
US (2) US20190321449A1 (lt)
EP (2) EP3995140A1 (lt)
JP (3) JP7316931B2 (lt)
KR (3) KR20190032614A (lt)
CN (2) CN109963582B (lt)
AU (3) AU2017312722B2 (lt)
BR (1) BR112019003172A2 (lt)
CA (1) CA3033051A1 (lt)
CL (1) CL2019000304A1 (lt)
CY (1) CY1124695T1 (lt)
DK (1) DK3484502T3 (lt)
ES (1) ES2899147T3 (lt)
HR (1) HRP20211628T1 (lt)
HU (1) HUE056294T2 (lt)
IL (2) IL264660B2 (lt)
LT (1) LT3484502T (lt)
MA (1) MA45692B1 (lt)
MD (1) MD3484502T2 (lt)
MX (1) MX2019001718A (lt)
NZ (1) NZ750885A (lt)
PL (1) PL3484502T3 (lt)
PT (1) PT3484502T (lt)
RS (1) RS62558B1 (lt)
SG (1) SG11201901273TA (lt)
SI (1) SI3484502T1 (lt)
UA (1) UA126232C2 (lt)
WO (1) WO2018034712A1 (lt)
ZA (1) ZA202004834B (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA48480A (fr) * 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
CN112469439A (zh) 2018-05-15 2021-03-09 万能溶剂有限公司 用白三烯a4水解酶调节剂治疗衰老相关性疾病
CN110724176B (zh) * 2018-07-16 2021-10-26 北京豪思生物科技有限公司 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用
CN110787187B (zh) * 2018-07-16 2022-05-13 北京豪思生物科技股份有限公司 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用
WO2020018343A1 (en) * 2018-07-20 2020-01-23 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MX2021004755A (es) * 2018-10-26 2021-06-08 Alkahest Inc Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
CN110448686B (zh) * 2019-09-19 2022-11-04 北京豪思生物科技股份有限公司 铜蓝蛋白联合运铁蛋白的应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
JP2022553837A (ja) 2019-11-04 2022-12-26 アルカヘスト，インコーポレイテッド 筋肉再生に使用するための血漿画分
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
US11660316B2 (en) 2019-11-20 2023-05-30 Alkahest, Inc. Methods of inducing liver regeneration by administering a plasma protein fraction
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3612137A1 (de) * 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
WO2002092121A1 (fr) * 2001-05-11 2002-11-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nouveaux remedes pour maladies neurodegeneratives
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
CA2721037C (en) 2008-04-15 2018-05-22 Talecris Biotherapeutics, Inc. Methods for preparing a concentrated plasma product formulation using ultrafiltration/diafiltration
US20090297485A1 (en) * 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
PL2994160T3 (pl) * 2013-05-06 2019-10-31 Baxalta Inc Leczenie subpopulacji osób z chorobą alzheimera z użyciem połączonej immunoglobuliny g
WO2015088915A1 (en) 2013-12-09 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
EA039316B1 (ru) * 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
MA48480A (fr) * 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Also Published As

Publication number Publication date
RS62558B1 (sr) 2021-12-31
HRP20211628T1 (hr) 2022-02-04
US20190321449A1 (en) 2019-10-24
ES2899147T3 (es) 2022-03-10
WO2018034712A1 (en) 2018-02-22
CY1124695T1 (el) 2022-07-22
IL304946A (en) 2023-10-01
ZA202004834B (en) 2022-07-27
CA3033051A1 (en) 2018-02-22
KR20220107322A (ko) 2022-08-02
JP2022037124A (ja) 2022-03-08
IL264660A (lt) 2019-04-30
AU2021240142A1 (en) 2021-10-28
KR20190032614A (ko) 2019-03-27
PT3484502T (pt) 2021-11-18
CL2019000304A1 (es) 2019-05-31
UA126232C2 (uk) 2022-09-07
CN109963582A (zh) 2019-07-02
KR20240036720A (ko) 2024-03-20
MA45692A (fr) 2019-05-22
CN115957309A (zh) 2023-04-14
PL3484502T3 (pl) 2022-01-31
IL264660B2 (en) 2024-03-01
AU2017312722A1 (en) 2019-03-14
JP2019528269A (ja) 2019-10-10
EP3484502B1 (en) 2021-08-25
US20220152161A1 (en) 2022-05-19
CN109963582B (zh) 2022-12-27
SG11201901273TA (en) 2019-03-28
IL264660B1 (en) 2023-11-01
MD3484502T2 (ro) 2022-01-31
JP7447069B2 (ja) 2024-03-11
DK3484502T3 (da) 2021-10-25
SI3484502T1 (sl) 2022-01-31
JP7316931B2 (ja) 2023-07-28
MX2019001718A (es) 2019-09-13
AU2020200181A1 (en) 2020-01-30
MA45692B1 (fr) 2021-10-29
BR112019003172A2 (pt) 2019-05-28
NZ750885A (en) 2021-07-30
EP3484502A1 (en) 2019-05-22
HUE056294T2 (hu) 2022-02-28
EP3484502A4 (en) 2020-03-04
AU2017312722B2 (en) 2020-01-02
AU2020200181B2 (en) 2021-07-22
JP2023156459A (ja) 2023-10-24
EP3995140A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
ZA202004834B (en) Blood plasma fractions as a treatment for aging-associated cognitive disorders
IL288712B1 (en) Methods for treating abnormal movement disorders
HK1258518A1 (zh) 用於眼病的基因療法
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HK1252996A1 (zh) 用於治療癲癇的方法
EP3119911A4 (en) Methods for treating neurological disorders
IL267229A (en) Methods of treating ocular disorders
HK1257272A1 (zh) 治療hiv的工具
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL259381B (en) Miravegron for the treatment of retinal diseases
RS63859B1 (sr) N,n-bis-2-merkaptoetil izoftalamid za lečenje neurodegenerativnih bolesti
ZA201707232B (en) Treatment of a hydrocarbon component
GB201616286D0 (en) Plasma abatement
GB201616285D0 (en) Plasma abatement
GB201602784D0 (en) New treatment of CFTR-related disorders